heterogeneous nuclear ribonucleoprotein L likeGenealiases: HNRPLL · SRRF
Q-omics provides the consensus-scored HNRNPLL profile across patient tissues and cancer cell-line models. HNRNPLL expression is associated with patient survival in 23 of 34 cancer types, with the highest sampling consensus in LIHC. Among the 18 cancer types available for tumor–normal comparison, HNRNPLL is differentially expressed in 12, with the highest sampling consensus in HNSC. Additionally, HNRNPLL protein abundance shows 25,826 significant protein co-abundance associations, with the highest sampling consensus in GBM. Together, these results highlight LIHC, HNSC, and GBM as cancer lineages where HNRNPLL shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for HNRNPLL — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes HNRNPLL survival associations across molecular data types. HNRNPLL RNA expression shows survival associations in the most cancer types (23), followed by mass-spec protein abundance (5). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible HNRNPLL RNA expression–survival associations across cancer types. High HNRNPLL expression shows unfavorable associations in LIHC, ACC, UVM and MESO, but favorable associations in KIRC and THYM. The LIHC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify LIHC as the clearest survival context for HNRNPLL RNA expression.
This table summarizes HNRNPLL tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 12, while mass-spec protein shows differences in 5. The strongest signals are observed in HNSC for RNA and CCRCC for protein.
This table ranks reproducible tumor–normal expression differences for HNRNPLL. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. HNRNPLL shows lower tumor expression in KICH and THCA and higher tumor expression in HNSC, LIHC, COAD and STAD. The HNSC box plot shows higher HNRNPLL RNA expression in tumor versus normal tissue (log2 FC = +0.919, t-test p < 0.001).
This table shows molecular features associated with HNRNPLL in patient tissues and cancer cell lines. In patient samples, HNRNPLL shows the broadest associations at the RNA and protein expression levels, with GBM recurring as the lineage with the largest associated feature set. In cancer cell lines, HNRNPLL RNA and mutation anchors are most strongly linked to RNA-expression features, especially in OVARY, while CRISPR and shRNA rows add functional-dependency signals in LUNG_SCLC and UPPER_AERODIGESTIVE_TRACT.
